Shares of Hanmi Pharm, GC strong on potential CMO deal for Moderna vaccines
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Their shares have been on a roll since Moderna late last year confirmed Korean procurement of coronavirus vaccine doses for 20 million people to South Korea for delivery starting May.
Shares of Hanmi Pharmaceutical with the sole capacity in Korea to roll out mRNA-based shots jumped 4.4 percent to close at 378,000 won ($347.97) on Wednesday. They have gained sharply since 330,000 won on Dec. 28.
Unlike traditional vaccines that contain either weakened viruses or purified signature proteins of the virus, mRNA vaccine delivers genetic material mRNA that encodes the viral protein to induce immune reaction in the human body. It is known to have fewer side effects but there are few plants to manufacture this new technology vaccine across the world.
In 2018, Hanmi completed a 20,000-liter cell culture and purification system at Pyeontaek, which is the only facility to enable mRNA vaccine production not only in Korea but also in Asia. The Pyeontaek plant is now able to churn out up to 1 billion doses of Covid-19 shots per year.
Hanmi Pharmaceutical confirmed that it is in talks with multiple vaccine developers including Moderna for a CMO deal but declined comment on details including the companies in negotiations.
GC Pharma is another Korean pharmaceutical company that can produce Covid-19 vaccines as a CMO. The company already signed a contract with the Coalition for Epidemic Preparedness Innovations (CEPI) to fill and package more than 500 million doses of coronavirus vaccines for 14 months from March.
Its shares also gained sharply since Dec. 28 finish of 354,000 won. They closed down 3 percent at 427,000 won on Wednesday after going as high as 467,500 won.
Other potential vaccine CMOs in Korea are SK Bioscience and Samsung Biologics. But the two have existing assignments for other vaccine developers and thus little room for Moderna vaccines.
Some say Moderna could assign a Korean partner to import and distribute its vaccine instead of production as contract manufacturing involves technology transfer and carries a business risk for the developer.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Shares of Hanmi Pharm, GC strong on potential CMO deal for Moderna vaccines - Pulse by Maeil Business News Korea
- Kakao Enterprise bags $92 mn investment from KDB, joins unicorn rank - Pulse by Maeil Business News Korea
- BTS “Dynamite” stays at Billboard singles top 10 longest for K-pop act - Pulse by Maeil Business News Korea
- Korea’s biohealth exports at record high last year, join 10 mainstay rank - Pulse by Maeil Business News Korea
- Korea’s kimchi exports record high in the year of pandemic - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 韓 배당 성향 26%…대만 절반 수준, ‘단타’만 횡행…세금은 여차하면 폭탄
- ‘김기리 ? 문지인’ 결혼식, 백지영·박진주 ‘축가’...“세기의 결혼식 방불케해”(종합) - MK
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이